Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ali Ghani

Interventional Cardiology Normal, IL Medical Doctor

NPI 1013392018 CMS profile 1326597

1302 Franklin Ave Ste 4500, Normal, IL 61761

Open in the dashboard

General payments

$15,962

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ali Ghani of Normal, IL is reported in the CMS Open Payments database as having received $15,962 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,748 37
2024 General $3,108 16
2023 General $3,008 16
2022 General $1,243 17
2021 General $919 9
2020 General $218 3
2019 General $1,718 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ali Ghani
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ali Ghani were reported at $5,748. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ali Ghani Interventional Cardiology median Middle half National median
2019 $1,718 $1,097 $329–$3,048 $163
2020 $218 $473 $161–$1,480 $114
2021 $919 $677 $233–$1,827 $132
2022 $1,243 $978 $333–$2,724 $149
2023 $3,008 $1,136 $382–$2,986 $160
2024 $3,108 $1,181 $395–$3,326 $164
2025 $5,748 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $4,083 44 payments
  2. Medtronic, Inc. $3,696 12 payments
  3. Boston Scientific Corporation $3,046 14 payments
  4. Abiomed $2,206 11 payments
  5. Penumbra, Inc. $1,576 10 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $360 6 payments
  7. AstraZeneca Pharmaceuticals LP $232 3 payments
  8. Edwards Lifesciences Corporation $194 5 payments
  9. Cardiovascular Systems Inc. $120 1 payment
  10. Teleflex LLC $116 1 payment
  11. Other $331 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $7,483 31 payments
  2. Food and Beverage $4,938 80 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $3,067 1 payment
  4. Education $390 4 payments
  5. Gift $84 1 payment
Products named General payments · program years 2019–2025
  1. VersaCross Access Solution $2,782 12 payments
  2. Impella $2,206 11 payments
  3. Indigo System $1,576 10 payments
  4. Ensite Cardiac Mapping System $1,267 12 payments
  5. MITRACLIP $1,238 11 payments
  6. SUPERA $520 3 payments
  7. LifeVest $360 6 payments
  8. Perclose ProGlide suture mediated closure system $246 3 payments
  9. Assurity Pacemaker $225 4 payments
  10. RESOLUTE ONYX $214 1 payment
  11. Other $2,029 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,893

Median for Interventional Cardiology: 2,236

Drug cost

$313,273

Median for Interventional Cardiology: $380,412

Branded share of claims

22.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 69 $80,968
Repatha Sureclick Evolocumab Brand 38 $55,689
Xarelto Rivaroxaban Brand 39 $49,376
Entresto Sacubitril/Valsartan Brand 39 $46,507
Jardiance Empagliflozin Brand 42 $41,847
Brilinta Ticagrelor Brand 20 $17,322
Vascepa Icosapent Ethyl Brand 13 $4,799
Metoprolol Succinate Generic 299 $3,617
Ranolazine Er Ranolazine Brand 16 $1,983
Midodrine Hcl Generic 13 $1,812

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$68,189

Medicare's payments for the services billed

Medicare patients

373

Average age 75

Services billed

951

204 women, 169 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Heart failure 49%
Arthritis 49%
Chronic kidney disease 45%
Diabetes 44%
Atrial fibrillation 35%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record